Engflag

Vivian

Quick links to important sections

Vivian

Vivian_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vivian

Quick Facts

Property Description
Active Ingredients Diclofenac Sodium, Linseed Oil, Menthol, Methyl Salicylate
Form Topical Gel
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID) and Topical Analgesic/Counterirritant
Common Purpose Localized relief from pain and inflammation
Origin Combination of semi-synthetic and plant-derived compounds
Target Audience Focus Active adults experiencing musculoskeletal pain

What Type of Medicine is Vivian? (Identity and Classification)

Vivian is a proprietary, fixed-dose multi-component topical preparation classified as a combination drug that combines a core Non-Steroidal Anti-Inflammatory Drug (NSAID) with specialized topical analgesic and counterirritant agents. The inclusion of Diclofenac Sodium, an NSAID, establishes the drug's primary action. This formulation is typically positioned for the management of localized, acute musculoskeletal discomfort in active adults. The designation as a Topical Gel means the product is intended solely for external application, focusing the therapeutic effect directly on the area of need.

What is the Composition of Vivian Gel? (Ingredients and Origin)

the efficacy of Vivian is based on the synergy of four key active ingredients: Diclofenac Sodium, Linseed Oil, Menthol, and Methyl Salicylate. This composition draws from both semi-synthetic sources (like the NSAID Diclofenac) and natural/plant-derived compounds (Linseed Oil, Menthol). The Diclofenac provides the core molecular anti-inflammatory action, while Methyl Salicylate and Menthol contribute sensory effects. Linseed Oil is included in the formulation for its role in enhancing the percutaneous absorption of active agents, leading to local tissue delivery. This feature differentiates the gel from standard, single-active-ingredient Diclofenac preparations.

What is the General Purpose of This Combination Drug? (High-Level Benefit)

The general purpose of this multi-component product is to offer an integrated approach to localized pain and inflammation. By utilizing complementary physiological actions, the formulation is designed to provide initial comfort through the counterirritant and analgesic effects, while the NSAID works concurrently to address the underlying inflammatory process. This dual strategy ensures the preparation addresses both the symptom—the felt discomfort—and the physical cause—the swelling—in the affected area.

What side effects are possible with Vivian?

The official safety documentation for this multi-component topical gel focuses primarily on local application-site reactions, with secondary consideration given to the systemic risks associated with the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.

Adverse Reaction Classification

The most commonly documented adverse events are typically localized to the skin and classified as Common in regulatory sources. These include dermatitis (such as contact dermatitis), pruritus (itching), erythema (redness), and rash at the area of application. A localized burning sensation may also be experienced due to the counterirritant components.

Less frequently, Rare and Very Rare systemic events documented in the NSAID class safety profile must be considered, including generalized hypersensitivity reactions like angioedema and severe cutaneous adverse reactions (SCARs). The official labeling for the NSAID component also covers the risk of anaphylactic reactions and the precipitation of asthma in susceptible individuals.

Safety Considerations and Restrictions

Certain regulatory restrictions apply based on the potential for systemic exposure. The product is contraindicated in patients with a history of asthma, urticaria, or other allergic reactions precipitated by aspirin or other NSAIDs. Use is generally avoided in women starting at 30 weeks of gestation (the third trimester of pregnancy) due to the risk of premature closure of the fetal ductus arteriosus. Furthermore, the gel must not be applied to damaged, infected, or eczematous skin, and contact with eyes and mucous membranes must be avoided. Local adverse reactions are documented as generally more likely to occur at the start of treatment.

Overdose and Emergency Response

The official regulatory documents define the systemic overdose profile of Vivian Gel, primarily referencing effects similar to those observed after substantial ingestion of its NSAID component.

Overdose Presentation Key Clinical Manifestations
Common Systemic Signs Acute systemic overdose may present with lethargy, drowsiness, nausea, vomiting, and epigastric pain. These initial manifestations are typically described in regulatory texts as reversible with supportive care.
Serious or Life-Threatening Outcomes Documented potential for severe, non-reversible complications impacting multiple organ systems, including gastrointestinal bleeding, acute renal failure, respiratory depression, hypertension, and coma. Anaphylactoid reactions are also listed as a severe risk.

Official Emergency Actions and Management

Mandated emergency actions require that professional medical attention must be sought immediately following known substantial ingestion of the gel. Urgent help is also required for the onset of any severe systemic manifestations, such as signs of gastrointestinal bleeding, sudden respiratory depression, or indications of severe neurological compromise. The official management framework confirms that treatment is strictly symptomatic and supportive, as regulatory labeling confirms that no specific antidote is known for this toxicity. Clinical observation and monitoring are necessary until all severe systemic signs have fully resolved.

Therapeutic Uses of Vivian

Quick Facts

  • Relief from discomfort associated with arthritis and injuries
  • Assists in managing symptoms of rheumatoid arthritis
  • Supports pain management in cases of osteoarthritis
  • Indicated for symptom control of ankylosing spondylitis
  • Used for temporary relief of pain and inflammation

What Vivian Treats: Main Uses and Benefits

Vivian is a medication utilized in the management of pain and discomfort across several conditions. The primary therapeutic domains involve addressing symptoms associated with joint and muscle conditions.

This medication is customarily provided to help mitigate pain and inflammation linked to chronic inflammatory disorders. The established uses include providing symptomatic relief for rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. In these contexts, Vivian is part of a comprehensive strategy to manage the stiffness and pain that characterize these conditions.

Additionally, this drug is an option for the short-term management of mild to moderate pain, such as that associated with acute musculoskeletal injuries, strains, and sprains. It may also be used in the clinical setting to address pain following certain surgical procedures. The goal of treatment is to support improved function and comfort levels.

Vivian is an established non-steroidal anti-inflammatory drug (NSAID) which is an authorized therapeutic option for these indications. Patients should always consult a licensed healthcare provider to determine if this treatment is appropriate for their specific health needs.

Eligibility and Restrictions for Use

Vivian is a topical Non-Steroidal Anti-Inflammatory Drug (NSAID) combination, and its population eligibility profile is strictly defined by regulatory rules applicable to the Diclofenac component. The medicine is contraindicated and must not be used by certain populations, primarily due to the risk of serious systemic effects documented in official labeling.

Eligibility Status Population or Condition
Contraindicated Known hypersensitivity to diclofenac, aspirin, or any NSAID.
Third trimester of pregnancy (starting at 30 weeks gestation).
For pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery.
Children and adolescents under 14 years of age (efficacy and safety are not established).

The gel must not be applied to non-intact skin, open wounds, or mucous membranes. Use is not recommended for nursing mothers, or during the first and second trimesters of pregnancy unless use is deemed explicitly necessary. Caution is advised when the medicine is used in older adults and in patients with underlying mild-to-moderate renal or hepatic impairment, as official documents indicate that systemic exposure, though low, can affect these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Vivian (Diclofenac Sodium Topical Gel) is governed by its active Non-Steroidal Anti-Inflammatory Drug (NSAID) component, Diclofenac, based on regulatory documentation.

Documented Drug-Drug Interactions

Co-administration is officially not generally recommended with other oral NSAIDs or aspirin (analgesic doses), as this significantly increases the risk of serious adverse effects, including gastrointestinal bleeding. Similarly, using Vivian with anticoagulants like Warfarin or antiplatelet agents increases the risk of bleeding. The medication may also diminish the therapeutic effects of certain cardiovascular agents, including ACE Inhibitors, ARBs, and diuretics (Furosemide, Thiazides).

Exposure-Modifying Substances

The regulatory label notes that Diclofenac can increase the systemic concentration of specific co-administered drugs. This may increase the toxicity risk for agents such as Digoxin, Lithium, Methotrexate, and Cyclosporine.

Interaction Restrictions

Use is contraindicated in the setting of perioperative pain management for Coronary Artery Bypass Graft (CABG) surgery. Additionally, other topical products (e.g., sunscreens or lotions) must not be applied to the same skin sites concurrently. Exposure of the treated area to natural or artificial sunlight should be avoided. A specific population note advises caution when combining Vivian with ACE Inhibitors or ARBs in the elderly or those with impaired renal function, due to the potential for renal function deterioration.

Mechanism of Action

Modulation of Inflammatory Chemical Messengers

Vivian acts primarily by inhibiting specific enzymes (Cyclooxygenase, or COX) in the body that are responsible for creating prostaglandins—the chemical messengers synthesized during the cyclooxygenation process. This targeted enzyme blockade reduces the rate of chemical signaling at the site of tissue irritation or damage, resulting in decreased concentrations of inflammatory mediators.

Modulation of Nociceptive and Thermoregulatory Signaling

The reduction in peripheral prostaglandin levels leads to a direct effect on the nociceptive pathway. Prostaglandins normally enhance the sensitivity of peripheral pain-sensing nerve endings; therefore, reducing their presence reduces the chemical sensitization of these pathways, resulting in decreased transmission of nociceptive signals to the brain.

Simultaneously, the mechanism extends to the brain's thermoregulatory center (hypothalamus), where it also suppresses COX activity. This central action alters the set-point signaling of this pathway, leading to predictable physiological adjustments of the core body temperature set-point.

Dosage and Administration Information

How to use Vivian: Administration Guidelines

Vivian is designed exclusively for topical administration, intended solely for application onto the skin overlying the affected joint. The route of use is strictly limited to external application, consistent with the product's classification as a topical gel.

Dosing and Frequency

The use of Vivian involves precision measurement using the specialized dosing card provided with the product. For joints in the upper extremities (such as the hand or wrist), the standard labeled dose is 2 grams per application. For lower extremities joints (such as the ankle or knee), the dose is 4 grams. The administration schedule involves application four times daily (QID).

The total amount applied across all affected joints must not exceed 32 grams per day. General therapeutic principles for this class of medication suggest using the lowest effective dose for the shortest duration necessary, particularly for older adults.

Application Protocol

The gel must be applied to clean, dry, intact skin and gently massaged over the painful area. To ensure proper absorption, specific time constraints must be observed after application. The treated area must not be washed, showered, or bathed for a minimum of one hour.

Furthermore, the area should remain uncovered by clothing or gloves for at least 10 minutes to allow the gel to absorb fully. The concurrent use of external heat or occlusive dressings/bandages over the treated area is avoided, and the drug must not be applied to more than two body areas simultaneously. For acute conditions, the duration of use for temporary relief is typically limited to 21 days unless otherwise advised.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vivian

Evidence for Use in Acute Musculoskeletal Pain

The research behind this formulation, specifically the topical Diclofenac component, primarily relies on short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, examining the outcomes related to physical discomfort in adults who had experienced recent soft-tissue injuries such as muscle strains, sprains, or contusions. Studies monitored patient-reported outcomes describing perceived discomfort over defined time intervals. Findings describe patterns observed in the studies where measurements of pain intensity and functional capacity over short periods were observed to differ between the active gel group and the inactive control. Limited information for long-term outcomes exists regarding how the treatment may influence the risk of recurring injury.

Evidence for Chronic Pain Management in Osteoarthritis

The research base for the therapeutic class of topical Diclofenac has often explored the symptomatic management of osteoarthritis (OA), a condition characterized by fluctuating or episodic manifestations. The evidence base includes multiple RCTs and high-quality systematic reviews and meta-analyses. Studies explored the formulation's influence on functional limitations and symptoms where pain and stiffness may vary in intensity. Findings indicate patterns of changes measured during the study period that differed between the active gel group and the placebo gel group. Comparative evidence is lacking specifically for the four-component combination versus standard Diclofenac gel; therefore, regulatory conclusions are typically based on the data patterns observed for the core NSAID component in a topical form.

What Research Still Seeks to Clarify

The current evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking in high-quality head-to-head trials to definitively separate the results of this specific multi-component formula (Diclofenac, Linseed Oil, Menthol, Methyl Salicylate) from those of a standard, single-active topical Diclofenac gel. Furthermore, long-term functional outcomes are not fully established based on single large-scale RCTs; instead, evidence relies on the aggregation of observational data and extended patient observation.

Key Studies & References

  1. Topical NSAIDs for acute pain: a meta-analysis (2004)
  2. Diclofenac - StatPearls (NIH, used for regulatory indications and context)

Frequently Asked Questions (FAQ)

Common questions about Vivian (FAQ)

Q: Does Vivian have a generic version available?

A: According to official product information, Vivian is currently available only as a brand-name medicine. A generic version, which would contain the same active ingredient, is not listed as being available at this time.

Q: What is the primary condition that Vivian is used to treat?

A: Regulatory documents state that Vivian is primarily indicated for the treatment of Major Depressive Disorder (MDD). It is authorized for use in managing the symptoms associated with this condition.

Q: What is the active ingredient in Vivian?

A: The active ingredient in Vivian is the compound known as sertraline hydrochloride. This is the component responsible for the medicine's intended therapeutic effect as described in the official product labeling.

Q: How long does it usually take to notice the effect of Vivian?

A: Studies and official information indicate that it may take several weeks for patients to experience benefits from Vivian. Official guidance indicates that it may take 4 to 6 weeks for the medicine's full therapeutic effect to be observed.

Q: What happens if I miss a dose of Vivian?

A: Official guidance suggests that if a dose is missed, it may be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If that is the case, the missed dose should generally be skipped, and the regular schedule continued. Official product information notes that double-dosing to compensate for a missed dose is not advised.

Q: Is Vivian a type of SSRI medicine?

A: Yes, regulatory documents classify Vivian as a selective serotonin reuptake inhibitor (SSRI). This type of medicine works by affecting the reuptake of serotonin, a natural substance in the brain, which contributes to improving mood.

How should Vivian be stored and disposed of?

Storage and Environmental Control

Vivian Gel must be stored strictly within the conditions specified by the official product label. The medicine must be stored at a temperature that does not exceed 30 C and must be kept from freezing.

Storage Requirement Official Condition
Temperature Store below 30 C (Room Temperature)
Light/Handling Keep from freezing and protect from light
Child Safety Keep out of the reach of children

The product should be stored in its original, closed container and kept away from excess heat and moisture to maintain the labeled 36-month shelf life. Do not keep medicine that is outdated or no longer needed.

Disposal Instructions

Unused or expired Vivian Gel must be disposed of in accordance with local requirements. The best option is to utilize an authorized drug take-back program (e.g., pharmacy or police station drop-off). If a take-back program is unavailable, the gel may be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a plastic bag, and placed in the household trash. Disposal via wastewater must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vivian found in:

A-Z Index: